ALXO Stock - ALX Oncology Holdings Inc.
Unlock GoAI Insights for ALXO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $1.18M |
| Gross Profit | N/A | N/A | N/A | N/A | $107,000 |
| Gross Margin | N/A | N/A | N/A | N/A | 9.1% |
| Operating Income | $-142,467,000 | $-170,278,000 | $-127,436,000 | $-83,555,000 | $-43,663,000 |
| Net Income | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 | $-45,740,000 |
| Net Margin | N/A | N/A | N/A | N/A | -3869.7% |
| EPS | $-2.58 | $-3.74 | $-3.03 | $-2.07 | $-1.28 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | Jefferies | Initiation | Buy | $4 |
| March 6th 2025 | Jefferies | Upgrade | Buy | $3← $2 |
| December 19th 2024 | Jefferies | Downgrade | Hold | $2← $12 |
| March 8th 2024 | Stifel | Downgrade | Hold | $14← $10 |
| December 8th 2023 | Jefferies | Upgrade | Buy | $18← $8 |
Earnings History & Surprises
ALXOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.38 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.37 | $-0.41 | -10.8% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.46 | $-0.49 | -6.5% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.47 | $-0.58 | -23.4% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $-0.72 | $-0.55 | +23.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.78 | $-0.58 | +25.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.77 | $-0.76 | +1.3% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.87 | $-0.71 | +18.4% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.84 | $-0.93 | -10.7% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.86 | $-1.24 | -44.2% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.85 | $-0.84 | +1.2% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.84 | $-0.58 | +31.0% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-0.91 | $-0.60 | +34.1% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.75 | $-0.72 | +4.0% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.66 | $-0.67 | -1.5% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.77 | $-0.46 | +40.3% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.63 | $-0.56 | +11.1% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $-0.47 | $-0.51 | -8.5% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.42 | $-0.34 | +19.0% | ✓ BEAT |
Latest News
ALX Oncology Announced Earlier Sunday, Combination Of Evorpacept Plus Rituximab And Lenalidomide Generated Complete Responses In 92% Of Patients With Untreated Indolent Non-Hodgkin Lymphoma Comparing Favorably To ~50% Historical CR Rate For R2 Alone
📈 PositiveALX Oncology Holdings Q3 Adj. EPS $(0.36) Beats $(0.37) Estimate
📈 PositiveALX Oncology Presents Preclinical Data And Trial Design For Ongoing Phase 1 Clinical Trial For ADC Candidate, ALX2004, In Two Poster Presentations At 2025 AACR-NCI-EORTC Conference
➖ NeutralALX Oncology Holdings To Present Updated Data From Phase 2 ASPEN-06 Trial During Poster Session At SITC Annual Meeting
📈 PositiveALX Oncology Announces First Patient Dosed In Phase 1 Clinical Trial For ALX2004, EGFR ADC That Is Being Studied For Treatment Of EGFR-Expressing Solid Tumors
📈 PositiveFrequently Asked Questions about ALXO
What is ALXO's current stock price?
What is the analyst price target for ALXO?
What sector is ALX Oncology Holdings Inc. in?
What is ALXO's market cap?
Does ALXO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALXO for comparison